Psychedelic therapy: Investors brace for paradigm shift

Drug laws stand in way

clock • 6 min read
Widespread use of psychedelics in therapy would be 'paradigm shift'
Image:

Widespread use of psychedelics in therapy would be 'paradigm shift'

In November 2021, the largest ever trial into the therapeutic benefits of psilocybin concluded that the compound was effective in the treatment of serious depression.

Proof of the efficacy of psychedelics in helping people with mental illnesses previously deemed untreatable is building beyond the anecdotal evidence, but researchers continue to face an uphill struggle while investors wait for more opportunities in the psychedelic realm. Many of the psychedelic compounds researchers are working with are still classified as Schedule 1 under the 1971 UN Convention of Psychotropic Substances, meaning they are lumped into the same category as heroin, cocaine and amphetamines. "Schedule 1 is meant for drugs that are an especially serious risk to public he...

To continue reading this article...

Join Investment Week

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Equities

Alternative proteins primary area for investment.

VanEck launches space and sustainable food ETFs

Space tourism and food tech

clock 29 June 2022 • 2 min read
Daryl Liew, CIO at REYL Singapore.

REYL's Liew eyes return to overweight positions in Asian quality growth names

'It's a question of timing'

clock 28 June 2022 • 3 min read
Industry Voice: T. Rowe Price's 2022 Midyear Market Outlook summary

Industry Voice: T. Rowe Price's 2022 Midyear Market Outlook summary

Transitioning to a new paradigm

Ritu Vohora, Investment Specialist, Capital Markets at T. Rowe Price
clock 23 June 2022 • 2 min read
Trustpilot